Pharmacokinetics of Escalating Doses of Intravenous Repinotan in Healthy Male Volunteers

@article{Heinig2005PharmacokineticsOE,
  title={Pharmacokinetics of Escalating Doses of Intravenous Repinotan in Healthy Male Volunteers},
  author={Roland Heinig and M B{\"o}ttcher},
  journal={Clinical Drug Investigation},
  year={2005},
  volume={25},
  pages={115-123}
}
AbstractObjective: To investigate the pharmacokinetics of intravenous (IV) repinotan, a potent selective full serotonin (5-HT1a) receptor agonist, after administration of escalating doses/infusion rates to healthy volunteers with extensive or poor metaboliser phenotype, and to compare weight-adjusted (mg/kg) to fixed (mg/ day) dosing regimens. Subjects and methods: The pharmacokinetic profile of IV repinotan was evaluated in healthy male volunteers. In eight studies, extensive metabolisers… 

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke: Modified Randomized Exposure Controlled Trial (mRECT)

The mRECT demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test to achieve a targeted exposure to repinotan.

A Randomized , Double-Blind , Placebo-Controlled Trial to Evaluate the Efficacy , Safety , Tolerability , and Pharmacokinetic / Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke Modified

The Modified Randomized Exposure Controlled Trial (mRECT) demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test to achieve a targeted exposure to repinotan.

"A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/ pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke"

mRECT demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test

References

SHOWING 1-8 OF 8 REFERENCES

Polymorphic Drug Oxidation

The high incidence of PM (and of heterozygous extensive metabolisers) of S-mephenytoin in Asia might be the reason for the reported higher sensitivity of Orientals to diazepam compared with Caucasians.

Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view.

To summarize recent neuroprotective trials, there has been no useful balance of benefit over risk, and the message is accurate: the drugs or doses the authors tried were inadequate.

Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions

Key challenges and complexities in translational stroke research are reviewed by focusing on the “disconnect” in the way that neuroprotective agents have traditionally been assessed in clinical trials compared with animal models and new concepts in ischemic pathophysiology are explored.

Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies

The recommendations contained in this document may help to focus attention on how to achieve the goal of developing an expanding number of a effective and safe acute stroke therapies.